Clinical trials: Statin Dose
Acute Coronary Syndromes
Drug Interaction Statin
This purpose of this study is to assess the effects of BMS-919373 on the single dose Pharmacokinetics (PK) of Rosuvastatin and Atorvastatin in healthy subjects.
- Trial name
- NCT02089061
- Testing
- BMS-919373, Rosuvastatin, Atorvastatin
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
ST Elevation (STEMI) Myocardial Infarction
Microcirculation In Acute Coronary Syndromes
In this mechanistic pilot study in 40 patients the investigators will compare the findings in patients treated with very early high dose statin therapy with historic controls from the KOMPIS study published in EHJ 200925.
- Trial name
- MICROS (NCT01382472)
- Testing
- Rosuvastatin, Simvastatin
- Where
- 3 sites in Norway
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Acute Myocardial Infarction
To Investigate the Role of Upstream High Dose Statin in STEMI
This is a double-blinded randomized placebo controlled trial investigating the role of upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for acute STEMI.
- Trial name
- IMPRES (NCT01050348)
- Testing
- Atorvastatin calcium
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- The Western Pennsylvania Hospital
Covid19
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19
In a 2x2 factorial design randomized controlled trial, the investigators aim to elaborate the safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients with COVID-19.
- Trial name
- INSPIRATION (NCT04486508)
- Testing
- intermediate dose Enoxaparin/ unfractionated heparin, standard prophylactic dose Enoxaparin/ unfractionated heparin, Atorvastatin 20mg
- Where
- Iran
- Volunteers
- 600 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Acute Kidney Injury
Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery
Statins were reported to have pleiotropic effects including antiinflammatory, anti-oxidative stress effects and stabilise plaque in some conditions.
- Trial name
- NCT01547455
- Testing
- Atorvastatin(Lipitor)
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking Union Medical College
HDL Cholesterol
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)
Summary: Background: There is a lot of interest in the function and role of HDL to prevent and mitigate atherosclerosis in patients who are at or near LDLc targets.
- Trial name
- NCT00736463
- Testing
- Simvastatin, Atorvastatin 80 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Oregon Health and Science University
Atherosclerosis
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
To obtain safety and tolerability information in healthy subjects is administered as a single dose
- Trial name
- NCT01587365
- Testing
- BMS-962476
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Dyslipidemia
Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia
Statin therapy does not fully eliminate the cardiovascular disease (CVD) risk associated with low high density lipoprotein-C (HDL-C) and high triglyceride levels.
- Trial name
- NCT01010516
- Testing
- High-dose rosuvastatin, Statin plus fenofibrate, Statin plus niacin ER/laropiprant
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Ioannina
Statin Adverse Reaction
Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study
Statins are a class of cholesterol lowering medications that contribute to reducing a person's risk of experiencing a cardiovascular event like heart attack.
- Trial name
- NCT06874192
- Testing
- Low-dose colchicine at 0.5mg daily
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Hypertension, Dyslipidemia
Efficacy of Fixed-doses of Antihypertensive and Statin Drugs
The purpose of this study is to evaluate the efficacy of different fixed-dose combination of Viena II in treatment of hypertension and dyslipidemia.
- Trial name
- NCT03401580
- Testing
- Viena II 160/10, Viena II 190/10, Viena II 160/12
- Sponsor
- EMS
Hypercholesterolemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in…
- Trial name
- GAUSS-4 (NCT02634580)
- Testing
- Evolocumab, Ezetimibe
- Where
- 35 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Amgen
Hypercholesterolemia
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is…
- Trial name
- NCT01592240
- Testing
- PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316)
- Where
- 74 sites in United States
- Volunteers
- 354 people
- Sponsor
- Pfizer
Coronary Artery Disease
Low Dose Statins, Ezetimibe and Nutraceuticals
It remains unknown if the association between moderate to low intensity statin therapy and ezetimibe and nutraceuticals might have a therapeutic role in high-intensity statin intolerant patients
- Trial name
- TACO (NCT03277079)
- Testing
- statin + ezetimibe, statin + ezetimibe + Nutraceuticals
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab administration as add-on therapy to non-statin lipid modifying therapy (LMT) including diet therapy alone or the lowest…
- Trial name
- ODYSSEY-NIPPON (NCT02584504)
- Testing
- Alirocumab, Atorvastatin, Non-statin Lipid-Modifying Therapy
- Where
- 30 sites in Japan
- Volunteers
- 163 people
- Sponsor
- Sanofi
Myocardial Infarction, Statin Adverse Reaction
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg.
- Conditions
- Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
- Trial name
- ROSUZET-AMI (NCT04499859)
- Testing
- Ezetimibe 10mg + Rosuvastatin 5mg, Rosuvastatin 20mg
- Where
- 7 sites in South Korea
- Volunteers
- 3,548 people
- Sponsor
- Kiyuk Chang, MD,PhD
Hypercholesterolemia, Mixed Dyslipidemia
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®
In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination [FDC] with ezetimibe 10 mg) followed by a…
- Trial name
- NCT05546398
- Testing
- Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab, No study drug
- Where
- 63 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Statin Dose
Effective Dose of Statin Post PCI
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
- Trial name
- NCT04923152
- Testing
- moderate statin dose, high dose statin
- Where
- Iran
- Volunteers
- 582 people
- Sponsor
- Shiraz University of Medical Sciences
Cardiovascular Disease
High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)
The aim of this study is to compare the effect of high dose and low dose of Atorvastatin in reduction level of C-reactive protein (CRP) in patients with unstable angina and NSTEMI (Non ST Elevation MI) attending Shahid Mohammadi…
- Trial name
- NCT01306565
- Testing
- Low dose Atorvastatin, High dose atorvastatin
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Hormozgan University of Medical Sciences
Kidney Failure
PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography
The contrast induced kidney toxicity has been known to affect the mortality and morbidity in the patients undergoing coronary angiography. But the mechanism and therapeutic strategy for it is not well known.
- Trial name
- NCT00259441
- Testing
- Simvastatin
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Seoul National University Hospital
Atherosclerosis, Thromboembolism
Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).
- Conditions
- Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus
- Trial name
- NCT00371501
- Testing
- Rosuvastatin, aspirin
- Where
- Hong Kong
- Volunteers
- 72 people
- Sponsor
- Tuen Mun Hospital